Edesa Biotech Confirms Participation in 2024 Bloom Burton Healthcare Investor Conference

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company specializing in the development of therapeutics for immuno-inflammatory diseases, has announced its attendance at the Bloom Burton & Co. Healthcare Investor Conference. This event is set to take place in Toronto, Ontario, from April 16-17, 2024. Edesa's CEO, Par Nijhawan, MD, is slated to present on April 17 at 11:00 am ET.

Interested parties are invited to connect with Edesa management during the conference through the event's online portal or by direct contact at investors@edesabiotech.com. Edesa Biotech is at the forefront of creating innovative treatments for a variety of immune-related conditions, with multiple drug candidates undergoing clinical trials including their Phase 3 study aimed at treating Acute Respiratory Distress Syndrome (ARDS) with their leading drug, EB05.

The company has also outlined plans for further research, including a Phase 2 study of their drug for pulmonary fibrosis, and ongoing trials for drugs targeting vitiligo and chronic Allergic Contact Dermatitis (ACD). This announcement reflects Edesa's dedication to advancing healthcare through novel therapeutic solutions.